Israel-based medical device company CardiaCare has closed an oversubscribed seed extension funding round to support clinical pilot studies of its wearable technology for cardiac arrhythmias, including atrial fibrillation (AFib).
Led by Solardis Health Ventures, the round is intended to bolster CardiaCare’s clinical programme across several AFib-related indications.
Discover B2B Marketing That Performs
Combine business intelligence and editorial excellence to reach engaged professionals across 36 leading media platforms.
The company is developing a wearable platform intended to detect, monitor and non-invasively treat cardiac arrhythmias.
CardiaCare said the system is designed to allow physicians to monitor patients remotely while creating personalised neuromodulation treatments based on real-time condition data.
CardiaCare CEO Ofer Halbreich said: “The oversubscribed closure of this round is a reflection of the potential of CardiaCare’s technology to disrupt the standard of care for AFib. We are proud to have Solardis Health Ventures, along with savvy clinical and commercial leaders, support our journey.
“The funds will be used to support existing and future double-blind, multicentre clinical studies to demonstrate the clinical efficacy of CardiaCare’s therapy for various indications.”
Solardis Health Ventures founder and managing partner Amir Soltanianzadeh said: “CardiaCare’s novel approach to treating AFib using neuromodulation will be a paradigm shift for the millions of patients who have no alternatives to toxic drugs, cardioversion shock therapy, or invasive procedures.
“Solardis Health Ventures is proud to lead this round and support CardiaCare’s mission to become the first therapeutic wearable for cardiac arrhythmia patients.”
CardiaCare was founded by cardiac arrhythmia specialist and entrepreneur Amos Ziv to develop new AFib therapies, drawing on more than a decade of clinical experience.
